Iktos announced research alliance with Almirall for new drug design

By Nikita Chaurasia  | Date: 2019-12-14

Iktos announced research alliance with Almirall for new drug design
  • The new drug design to involve AI technology for optimization of advanced compounds and boosting up the identification if drug candidates for Almirall drug discovery program.
  • The agreement is likely to provide rapid identification of molecules for the satisfaction of multiple bioactivity for clinical trials.
  • Under the pact, Almirall would leverage Iktos’s AI accuracy to bring about a difference in the patients’ lives.

One of the prominent AI companies dealing in novel drug design, Iktos, has reportedly announced establishing a research partnership with leading skin-health focused pharmaceutical company, Almirall on the grounds of designing novel drug compounds via the use of Iktos’ AI technology.

As per reliable reports, Iktos’ AI technology offers high speed and efficiency to the drug discovery process through automatically designing virtual molecules that display desirable characteristics of an advanced drug candidate. This is apprehended to tacked one of the fundamental challenges in drug design which is the rapid and repetitive identification of molecules that authenticate the multiple bioactive attributes for testing.

On this acquisition, the executive Vice president R&D and Chief Scientific Officer of Almirall, Dr. Bhushan Hardas was quoted stating that the collaboration serves as an example of how the company intends to explore myriad possibilities served by the technology to discover new molecules and boost the clinical development. He further added that the company has planned to stand at the forefront of innovations to build holistic and transversal approaches in the medical field. AI is anticipated to offer Almirall a distinctive opportunity to amalgamate its skills with an intent to augmenting patients’ lives.

Meanwhile, the president and CEO of Iktos, Yann Gaston- Mathe, cited that the company is delighted to be partnered with Almirall as this collaboration would bolster the leadership position of the company in the domain of AI for new drug design. 

Iktos has of late announced umpteen collaborations and mergers with the biopharmaceutical companies where the company lays immense focus on accelerating the design of promising compounds.

Source credit: https://finance.yahoo.com/news/iktos-almirall-announce-research-collaboration-080100761.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...